Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Duncan

Emergency Medicine Elwood, IN Medical Doctor

NPI 1629090980 CMS profile 28565

1515 S 19Th St, Elwood, IN 46036

Open in the dashboard

General payments

$5,786

361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Duncan of Elwood, IN is reported in the CMS Open Payments database as having received $5,786 across 361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,331 78
2024 General $1,556 86
2023 General $1,106 71
2022 General $607 42
2020 General $199 15
2019 General $988 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Duncan
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Ronald Duncan were reported at $1,331. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Ronald Duncan Emergency Medicine median Middle half National median
2019 $988 $51 $18–$128 $163
2020 $199 $29 $16–$99 $114
2021 $0 $40 $18–$124 $132
2022 $607 $49 $20–$134 $149
2023 $1,106 $51 $22–$142 $160
2024 $1,556 $52 $22–$150 $164
2025 $1,331 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $873 44 payments
  2. AbbVie, Inc. $757 60 payments
  3. Pfizer Inc. $635 47 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $500 29 payments
  5. Lilly USA, LLC $446 31 payments
  6. Dexcom, Inc. $345 18 payments
  7. Novo Nordisk Inc $315 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $242 16 payments
  9. Amgen Inc. $199 11 payments
  10. Exact Sciences Corporation $169 10 payments
  11. Other $1,304 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,675 357 payments
  2. Education $111 4 payments
Products named General payments · program years 2019–2025
  1. Kerendia $500 29 payments
  2. FARXIGA $410 22 payments
  3. AIRSUPRA $386 16 payments
  4. Dexcom G6 Transmitter $345 18 payments
  5. VRAYLAR $335 24 payments
  6. NURTEC ODT $310 19 payments
  7. UBRELVY $246 22 payments
  8. QULIPTA $228 20 payments
  9. MOUNJARO $199 11 payments
  10. ELIQUIS $172 11 payments
  11. Other $3,790 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 199 drugs

Part D claims

14,173

Median for Emergency Medicine: 88

Drug cost

$1,203,402

Median for Emergency Medicine: $590

Branded share of claims

24.4%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 166 $205,100
Eliquis Apixaban Brand 190 $148,443
Jardiance Empagliflozin Brand 114 $108,992
Trulicity Dulaglutide Brand 48 $70,330
Farxiga Dapagliflozin Propanediol Brand 76 $58,201
Forteo Teriparatide Brand 11 $46,245
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $39,538
Tradjenta Linagliptin Brand 40 $31,167
Tresiba Flextouch U-200 Insulin Degludec Brand 11 $24,886
Linzess Linaclotide Brand 27 $23,625

The 10 drugs with the highest cost, of 199 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$59,344

Of which drugs: $17,858

Medicare patients

205

Average age 73

Services billed

1,149

102 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Diabetes 34%
Arthritis 33%
Chronic kidney disease 24%
Depression 24%
COPD 23%
Ischemic heart disease 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 46 46 $6,944
Pcv20 vaccine im 90677 Office 20 20 $5,504
Vaccine for influenza for injection into muscle 90662 Office 55 55 $4,500

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $213
$213 — —
VRAYLAR
  • AbbVie, Inc. $193
$193 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $120
$120 76 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $106
$106 — —
Auvelity
  • Axsome Therapeutics, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record